We are live on ! Find out more
Bellevue Group

Bellevue Group Portfolio holdings

AUM $4.75B Turnover 23.84%
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
Cap. Flow
+$76.2M
Cap. Flow %
1.6%
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24
Avg Time Held
4 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.7 years

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$190M
2
INSM icon
Insmed
INSM
+$168M
3
GILD icon
Gilead Sciences
GILD
+$130M
4
UTHR icon
United Therapeutics
UTHR
+$105M
5
BBIO icon
BridgeBio Pharma
BBIO
+$81.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$121M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.6M
3
RVMD icon
Revolution Medicines
RVMD
+$72.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$63.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.05%
3 Technology 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PTGX icon
76
Protagonist Therapeutics
PTGX
$8.26B
$6.83M 0.14%
55,682
+41,235
+285% +$4.31M
2023 Q3
11 quarters
NTRA icon
77
Natera
NTRA
$56.4B
$6.73M 0.14%
24,806
-6,888
-22% -$1.47M
2022 Q4
14 quarters
TMDX icon
78
Transmedics
TMDX
$2.49B
$6.72M 0.14%
101,139
– –
2020 Q2
24 quarters
MOH icon
79
Molina Healthcare
MOH
$10.8B
$6.35M 0.13%
+27,761
New +$5.03M
2026 Q2
0 quarters
ALKS icon
80
Alkermes
ALKS
$6.73B
$6.3M 0.13%
120,243
+111,373
+1,256% +$4.35M
2025 Q3
3 quarters
RPRX icon
81
Royalty Pharma
RPRX
$27.2B
$6.3M 0.13%
112,311
+74,015
+193% +$3.85M
2025 Q3
3 quarters
WAY icon
82
Waystar Holding Corp
WAY
$5.25B
$6.03M 0.13%
293,592
+37,453
+15% +$788K
2024 Q2
8 quarters
PRVA icon
83
Privia Health
PRVA
$2.89B
$5.83M 0.12%
226,703
– –
2021 Q2
20 quarters
GMRS icon
84
GMR Solutions Inc
GMRS
$543M
$5.15M 0.11%
+333,333
New +$4.18M
2026 Q2
0 quarters
NBIX icon
85
Neurocrine Biosciences
NBIX
$13.8B
$4.05M 0.09%
24,037
+19,391
+417% +$2.88M
2016 Q1
41 quarters
OMDA icon
86
Omada Health Inc
OMDA
$1.11B
$3.47M 0.07%
157,938
– –
2025 Q2
4 quarters
KMTS icon
87
Kestra Medical Technologies
KMTS
$1.63B
$3.29M 0.07%
129,215
+13,625
+12% +$285K
2025 Q1
5 quarters
MDLN icon
88
Medline Inc
MDLN
$31.9B
$3.24M 0.07%
82,153
-54,482
-40% -$2.2M
2025 Q4
2 quarters
ILMN icon
89
Illumina
ILMN
$39.7B
$3.19M 0.07%
18,134
-2,089
-10% -$306K
2016 Q1
41 quarters
ONC icon
90
BeOne Medicines Ltd
ONC
$41.6B
$2.98M 0.06%
10,474
+6,662
+175% +$1.96M
2022 Q3
15 quarters
NAMS icon
91
NewAmsterdam Pharma
NAMS
$2.39B
$2.95M 0.06%
86,994
+59,333
+215% +$1.96M
2024 Q3
7 quarters
MDGL icon
92
Madrigal Pharmaceuticals
MDGL
$10.4B
$2.51M 0.05%
4,675
+1,635
+54% +$838K
2024 Q1
9 quarters
SPY icon
93
State Street SPDR S&P 500 ETF Trust
SPY
$807B
$2.02M 0.04%
2,700
– –
2024 Q4
6 quarters
BNTX icon
94
BioNTech
BNTX
$22.1B
$1.98M 0.04%
21,229
+378
+2% +$35.6K
2024 Q3
7 quarters
ADPT icon
95
Adaptive Biotechnologies
ADPT
$3.86B
$1.92M 0.04%
89,439
+13,258
+17% +$203K
2025 Q3
3 quarters
CYTK icon
96
Cytokinetics
CYTK
$8.65B
$1.62M 0.03%
19,007
+10,166
+115% +$730K
2022 Q1
17 quarters
ALMR icon
97
Alamar Biosciences
ALMR
$1.77B
$1.51M 0.03%
+55,738
New +$1.26M
2026 Q2
0 quarters
PHR icon
98
Phreesia
PHR
$680M
$1.45M 0.03%
140,495
+9,503
+7% +$88.2K
2019 Q3
27 quarters
MOBI icon
99
Mobia Medical
MOBI
$270M
$1.34M 0.03%
+100,000
New +$1.29M
2026 Q2
0 quarters
BLLN icon
100
BillionToOne Inc
BLLN
$4.62B
$1.27M 0.03%
10,554
– –
2025 Q4
2 quarters
2 3
4
5 6

Similar funds

Stockbridge Partners
Stockbridge Partners Boston, Massachusetts $4.75B AUM 18.52% 1-Year Est. Return
GTS Securities
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
SONA Asset Management (US)
SONA Asset Management (US) New York $4.76B AUM 23.76% 1-Year Est. Return
Local Pensions Partnership Investment
Local Pensions Partnership Investment London, United Kingdom $4.77B AUM 20.5% 1-Year Est. Return
Nicholas Hoffman & Company
Nicholas Hoffman & Company Atlanta, Georgia $4.74B AUM 18.12% 1-Year Est. Return
PTC
Provident Trust Company Waukesha, Wisconsin $4.77B AUM 29.31% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Truepoint Inc
Truepoint Inc Cincinnati, Ohio $4.79B AUM 16.42% 1-Year Est. Return

Bellevue Group's Q2 2026 Portfolio in Review

As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Technology.

  • Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
  • Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
  • Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
  • Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
  • Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.